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As patient-specific genetically engineered cell-based therapies begin to show efficacy in treating hematological 
malignancies, and potentially a far broader range of indications, attention has turned to developing methods to 
efficiently manufacturing such therapies. Products that are manufactured on a patient-by-patient basis can easily 
inherit the differences that are evident in the clinical presentation of individual patients, and as such may display 
vastly differing safety and efficacy profiles in different individuals. One solution to this problem lies in the ability to 
identify the critical to safety and efficacy attributes of patient-specific therapies and engineer these attributes into 
continuous cell lines that can subsequently be manufactured indefinitely in a consistent manner. This presentation 
will detail the unique challenges and opportunities associated with the clinical development of genetically-
engineered human induced pluripotent cell line-based natural killer and T cell-based therapies. It will also outline 
manufacturing processes that are designed to be immune to patient-to-patient variation, can reproducibly result in 
consistent safety and efficacy profiles and can facilitate on-demand availability of cost efficient cell-based 
therapies for a broad patient base.  
 
